To evaluate the cost-effectiveness of gene therapy for sickle cell disease in Uganda using a framework adapted from US economic data specifically tailored to local healthcare dynamics.
Key Findings:
Uganda's lifetime standard-of-care cost for SCD is estimated at $21,877, significantly lower than over $600,000 in the U.S., highlighting the need for price adjustments.
Casgevy is identified as the more viable gene therapy option, with its cost-effectiveness ratio falling within acceptable thresholds when adjusted for Uganda, particularly when considering societal benefits.
Lyfgenia, due to its higher price, is less likely to meet cost-effectiveness thresholds, emphasizing the importance of pricing in therapy selection.
Interpretation:
Affordability of gene therapies in Uganda is contingent on significant price reductions and the consideration of broader societal benefits, such as increased productivity and reduced caregiver burden.
Limitations:
The study relies on modeling and may not capture all local healthcare dynamics, which can vary widely.
Broader societal benefits are difficult to quantify and may vary widely, impacting the overall cost-effectiveness assessment.
Conclusion:
The study provides a framework to support equitable access to gene therapy in low-income settings, emphasizing the need for price adjustments and consideration of societal factors.
